Nearly two dozen women across the nation have filed lawsuits against a pharmaceutical giant over a contraceptive linked to a ...

Twenty-eight years after the incident, survivors lament how their lives have been negatively altered, writes VICTOR AYENI In ...

Pfizer trades at a 21.7% discount to peers on a 1-yr forward P/E basis, which is a point for the bullish arguments. Find out ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

One of Pfizer's recently acquired revenue sources, Padcev, earned approval to treat newly diagnosed bladder cancer patients ...

Pfizer yields 6.53% and trades at 9x earnings, while Altria offers 7.58% at 10.1x earnings. Pfizer's troubling 221% payout ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a ...

Despite today’s strength, Pfizer shares are trading deep in a long-term bear market trend. The stock crossed into bearish ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the ...

The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty ...

Revenue in 2025 will be $61 billion to $64 billion, Pfizer said, in line with predictions by Wall Street analysts.